This is a study to assess the efficacy of tiragolumab and Tecentriq® (atezolizumab) compared to placebo treatment in patients with locally advanced esophageal cancer.
Aim of the study
The study is designed to evaluate the safety and efficacy of tiragolumab and Tecentriq® (atezolizumab) compared to placebo treatment in patients with locally advanced esophageal cancer.
Who can take part?
Patients with locally advanced esophageal cancer
Procedure
In this clinical trial, you will receive either Tecentriq® plus tiragolumab, Tecentriq® plus placebo or a double placebo. Tiragolumab and Tecentriq® are investigational medicinal products. This means that the health authorities have not approved these drugs, either alone or in combination, for the treatment of esophageal cancer. All medication is administered as an infusion into the vein.
Compensation
None
Original study name
A randomized, double-blind, placebo-controlled phase III study of atezolizumab with or without tiragolumab (anti-tigit antibody) in patients with unresectable, locally advanced squamous cell carcinoma of the esophagus
BASEC number
2020-01826
Financial support from
Roche